.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BC04_Ropinirole.Ropinirole .Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BC04_Ropinirole.Ropinirole| name: | Ropinirole |
| ATC code: | N04BC04 | route: | oral |
| n-compartments | 1 |
Ropinirole is a non-ergoline dopamine agonist primarily used in the treatment of Parkinson's disease and restless legs syndrome. It is approved for clinical use in many countries, including the USA and Europe, for both indications.
Pharmacokinetic parameters reported for healthy adult male and female volunteers after single oral administration.
Kaye, CM, & Nicholls, B (2000). Clinical pharmacokinetics of ropinirole. Clinical pharmacokinetics 39(4) 243–254. DOI:10.2165/00003088-200039040-00001 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11069211
Hattori, N, et al., & Sakamoto, T (2012). Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease. Journal of clinical pharmacy and therapeutics 37(5) 571–577. DOI:10.1111/j.1365-2710.2012.01336.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22390368
Lai, KL, et al., & Lee, WYT (2018). Orally-dissolving film for sublingual and buccal delivery of ropinirole. Colloids and surfaces. B, Biointerfaces 163 9–18. DOI:10.1016/j.colsurfb.2017.12.015 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29268211